Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines

SIMPLE SUMMARY: The five-year survival rate for ovarian cancer is less than 50%, resulting in a global burden of >140,000 deaths annually. Late detection, cancer heterogeneity, and recurrent disease all contribute to treatment failure. Herein, recent advancements in the targeted delivery of thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Khetan, Riya, Dharmayanti, Cintya, Gillam, Todd A., Kübler, Eric, Klingler-Hoffmann, Manuela, Ricciardelli, Carmela, Oehler, Martin K., Blencowe, Anton, Garg, Sanjay, Albrecht, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140059/
https://www.ncbi.nlm.nih.gov/pubmed/35625966
http://dx.doi.org/10.3390/cancers14102362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140059/
https://www.ncbi.nlm.nih.gov/pubmed/35625966
http://dx.doi.org/10.3390/cancers14102362

Ejemplares similares